Evidence map›Paper›PMID 36986546›Full record

ReviewPharmaceuticals (Basel, Switzerland)2023

Application of Convergent Science and Technology toward Ocular Disease Treatment.

Ayça Bal-Öztürk, Ece Özcan-Bülbül, Hazal Ezgi Gültekin, Berivan Cecen, Ebru Demir, Atefeh Zarepour, Sibel Cetinel, Ali Zarrabi

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ayça Bal-ÖztürkDepartment of Stem Cell and Tissue Engineering, Institute of Health Sciences, Istinye University, Istanbul 34396, Türkiye.ORCID 0000-0002-6502-528X
Ece Özcan-BülbülDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Istinye University, Istanbul 34396, Türkiye.ORCID 0000-0001-7112-923X
Hazal Ezgi GültekinDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Izmir Katip Celebi University, Izmir 35620, Türkiye.
Berivan CecenDepartment of Mechanical Engineering, Rowan University, Glassboro, NJ 08028, USA.ORCID 0000-0002-0081-2004
Ebru DemirNanotechnology Research and Application Center (SUNUM), Sabanci University, Istanbul 34956, Türkiye.ORCID 0000-0002-9369-4149
Atefeh ZarepourDepartment of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Istinye University, Istanbul 34396, Türkiye.ORCID 0000-0002-0347-5840
Sibel CetinelNanotechnology Research and Application Center (SUNUM), Sabanci University, Istanbul 34956, Türkiye.ORCID 0000-0003-0248-9447
Ali ZarrabiDepartment of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Istinye University, Istanbul 34396, Türkiye.ORCID 0000-0003-0391-1769

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eyes are one of the main critical organs of the body that provide our brain with the most information about the surrounding environment. Disturbance in the activity of this informational organ, resulting from different ocular diseases, could affect the quality of life, so finding appropriate methods for treating ocular disease has attracted lots of attention. This is especially due to the ineffectiveness of the conventional therapeutic method to deliver drugs into the interior parts of the eye, and the also presence of barriers such as tear film, blood-ocular, and blood-retina barriers. Recently, some novel techniques, such as different types of contact lenses, micro and nanoneedles and in situ gels, have been introduced which can overcome the previously mentioned barriers. These novel techniques could enhance the bioavailability of therapeutic components inside the eyes, deliver them to the posterior side of the eyes, release them in a controlled manner, and reduce the side effects of previous methods (such as eye drops). Accordingly, this review paper aims to summarize some of the evidence on the effectiveness of these new techniques for treating ocular disease, their preclinical and clinical progression, current limitations, and future perspectives.

Indexed as

convergent sciencedrug deliverynanotechnologyocular diseasesmart contact lens

Identifiers

PMID36986546
PMCPMC10053244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.